DACS
IONS icon

Dymon Asia Capital (Singapore)’s Ionis Pharmaceuticals IONS Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,350
Closed -$423K – 275
2025
Q4 		$423K Buy
+5,350
New +$403K 0.04% 205

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s IONS Position: Q1 2026 in Review

Dymon Asia Capital (Singapore) sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 5,350 shares — an estimated $423K sold.

Dymon Asia Capital (Singapore) first reported a position in IONS in Q4 2025 and held it in 1 quarter. The position peaked at $423K in Q4 2025. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Dymon Asia Capital (Singapore) reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 5,350 Ionis Pharmaceuticals shares in Q1 2026, an estimated $423K.
  • Dymon Asia Capital (Singapore) first reported a position in Ionis Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Dymon Asia Capital (Singapore)'s Ionis Pharmaceuticals position peaked at $423K in Q4 2025.
  • 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q1 2026, filed 14 May 2026.